Intelligence Feed event · Policy · 2026-09-06

    Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics

    Question

    Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics

    Direct answer

    The global atopic dermatitis pharmaceutical market is forecast to expand at a 7.70% CAGR through 2035, reaching $33.42 billion. The transition toward specialty biologics and oral JAK inhibitors is driving volume growth across moderate-to-severe patient populations. Regeneron and AbbVie remain key commercial leaders, while competitive entries from Eli Lilly and Pfizer target market share expansion in systemic immunology.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-06
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics”, revision 1, evidence through 2026-09-06. https://marketontology.com/market-events/2026-09-06/atopic-dermatitis-therapeutic-market-projected-to-reach-33-42b-by-2035-on-biolog-5f6efc

    POLICY
    Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics
    The global atopic dermatitis pharmaceutical market is forecast to expand at a 7.70% CAGR through 2035, reaching $33.42 billion. The transition toward specialty biologics and oral JAK inhibitors is driving volume growth across moderate-to-severe patient populations. Regeneron and AbbVie remain key commercial leaders, while competitive entries from Eli Lilly and Pfizer target market share expansion in systemic immunology.
    REGNABBV
    Impact
    55
    SEP 6
    SIG
    75%
    REGNABBV
    Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologics
    The global atopic dermatitis pharmaceutical market is forecast to expand at a 7.70% CAGR through 2035, reaching $33.42 billion. The transition toward specialty biologics and oral JAK inhibitors is driving volume growth across moderate-to-severe patient populations. Regeneron and AbbVie remain key commercial leaders, while competitive entries from Eli Lilly and Pfizer target market share expansion in systemic immunology.
    → Expanding prescription volume for targeted biologics directly drives multi-year top-line franchise growth for REGN and ABBV.
    Impact
    The global atopic dermatitis pharmaceutical market is forecast to expand at a 7.70% CAGR through 2035, reaching $33.42 billion. The transition toward specialty biologics and oral JAK inhibitors is driving volume growth across moderate-to-severe patient populations. Regeneron and AbbVie remain key commercial leaders, while competitive entries from Eli Lilly and Pfizer target market share expansion in systemic immunology.
    Affected
    REGNABBV
    Transmission
    Expanding prescription volume for targeted biologics directly drives multi-year top-line franchise growth for REGN and ABBV.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    REGNbiologic franchise revenue expansionUp1-3mRegeneron listed among key leaders in atopic dermatitis biologics
    ABBVimmunology portfolio volume growthUp1-3mAbbVie identified as major participant in dermatology biologics and JAK inhibitors

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month